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Introduction
Irritable bowel syndrome (IBS) is a common gas-
trointestinal disorder characterised by abdominal 
pain, bloating and an alteration in bowel habits.1,2 
These criteria have been codified by the Rome 
Foundation and allow subtyping of IBS based on 
the predominant stool pattern, with subtypes 
including IBS with constipation (IBS-C), IBS 
with diarrhoea (IBS-D), IBS with a mixed stool 
pattern (IBS-M) and unclassified IBS (IBS-U), 
when the patient’s bowel habits cannot be accu-
rately categorised.2
According to the Rome III criteria, approxi-
mately 11.5% of the European population is 
estimated to be affected by IBS; IBS-C repre-
sents approximately one third of cases, although 
estimates vary.3–5 Prevalence estimates with the 
Rome IV criteria appear to be lower, suggesting 
that 7.5% of women and 3.6% of men in the 
UK are affected.6 IBS is associated with a sub-
stantial reduction in quality of life, greater 
health care resource use and increased costs.7 
In the UK, patients with IBS-C had signifi-
cantly greater health care resource use, greater 
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Abstract
Background: Linaclotide, a guanylate cyclase C agonist, has been shown in clinical trials to 
improve symptoms of irritable bowel syndrome with constipation (IBS-C). Here we report data 
from a real-world study of linaclotide in the UK.
Methods: This 1-year, multicentre, prospective, observational study in the UK enrolled 
patients aged 18 years and over initiating linaclotide for IBS-C. The primary assessment was 
change from baseline in IBS Symptom Severity Scale (IBS-SSS) score at 12 weeks, assessed 
in patients with paired baseline and 12-week data. Change from baseline in IBS-SSS score at 
52 weeks was a secondary assessment. Adverse events were recorded.
Results: In total, 202 patients were enrolled: 185 (91.6%) were female, median age was 
44.9 years (range 18.1–77.2) and 84 (41.6%) reported baseline laxative use. Mean (standard 
deviation) baseline IBS-SSS score was 339 (92), with most patients (n = 129; 66.8%) classified 
as having severe disease (score ⩾300). In patients with paired data, there was a significant 
mean (95% confidence interval) decrease in IBS-SSS score from baseline to 12 weeks [−77.0 
(−96.3, −57.7); p < 0.001; n = 124] and baseline to 52 weeks [−70.7 (−95.0, −46.5); p < 0.001; 
n = 76]. Overall, 174 adverse events were reported in 77 (38.1%) patients, most commonly 
diarrhoea (n = 54; 26.7%), abdominal pain (n = 21; 10.4%) and abdominal distension (n = 13; 
6.4%).
Conclusion: Linaclotide significantly improved IBS-SSS score at 12 and 52 weeks. These 
results provide insights into outcomes with linaclotide treatment over 1 year in patients with 
IBS-C in real-world clinical practice.
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work productivity impairment and poorer phys-
ical and mental health status versus matched 
controls.7,8
Patients with IBS-C are often recommended, and 
make use of, lifestyle modifications or over-the-
counter medications, such as fibre, nonprescrip-
tion laxatives or stool softeners, to manage their 
symptoms.9,10 However, these therapies are pri-
marily targeted at relief of a single symptom and 
are often associated with patient dissatisfaction, 
potentially resulting in the use of multiple thera-
pies as well as repeated switching of medica-
tions.10,11 Failure of existing treatment options to 
adequately control the symptoms of IBS-C has 
been shown to result in increased treatment costs 
and health care resource use.12
Linaclotide is a minimally absorbed, 14-amino-
acid peptide guanylate cyclase C agonist approved 
for the treatment of adults with moderate to 
severe IBS-C in the European Union,13,14 based 
on the results of two large phase III clinical trials 
demonstrating significant improvements in 
abdominal pain and bowel symptoms with lina-
clotide treatment versus placebo.15,16 However, 
data from the clinical trial setting may not accu-
rately reflect real-world experience in clinical 
practice.
We therefore aimed to assess the impact of lina-
clotide treatment in patients with IBS-C in a 
1-year, prospective, real-world study in the UK. 
Here we describe the results of this study at 12 
and 52 weeks from initiation of linaclotide 
treatment.
Methods
Study design
We undertook a 1-year, multicentre, prospective, 
observational, single-arm study conducted in the 
gastroenterology and specialist surgical depart-
ments of eight secondary or tertiary care centres 
in the UK, with recruitment occurring from 16 
January 2015 to 16 October 2015. There were no 
changes to patient management for the purposes 
of any part of this study and patients were not 
required to attend any visits in addition to their 
routine care, but were required to complete ques-
tionnaires during routine visits. The study obser-
vation period was 52 weeks in duration following 
the initiation of linaclotide for each patient. The 
use of concomitant treatments for IBS-C during 
the study was permitted, and patients withdraw-
ing from linaclotide treatment may have been 
offered other treatment options, which were not 
recorded as part of the study.
The study received independent NHS Research 
Ethics Committee (REC) approval from the East 
of England, Hatfield REC (reference 14-EE-
1221), and also received NHS Trust/Health Board 
Research and Development department approval 
at each study centre. All participants provided 
written, informed consent. Data can be obtained 
by contacting IR-medcom@allergan.com.
Study population
Eligible patients were men and women aged 
18 years and over who had been initiated on lina-
clotide therapy, at a standard dose of 290 Pg 
orally once daily, at a participating research cen-
tre as part of their usual care, and who were able 
and willing to complete questionnaires and con-
sented to their medical records being used for 
research purposes. The study aimed to achieve a 
high level of recruitment of patients initiating lin-
aclotide therapy at participating centres.
Study assessments
Efficacy assessments and endpoints. The primary 
objective of this study was to assess change in IBS 
Symptom Severity Scale (IBS-SSS) score from 
baseline to 12 weeks after linaclotide treatment 
initiation. Secondary objectives included change 
in IBS-SSS score from baseline to 52 weeks after 
linaclotide initiation, the proportion of patients 
responding to linaclotide treatment and change in 
quality of life, assessed with the IBS Quality of 
Life measure (IBS-QOL) and the EuroQoL, five-
item, three-level questionnaire (EQ-5D-3L), 
from baseline to 12 and 52 weeks.
The IBS-SSS has five domains scored from 0 to 
100, with the overall score reported on a scale of 
0–500. Higher scores indicate more severe symp-
toms, and a score reduction of 50 points is consid-
ered adequate to reliably indicate improvement.17 
Disease severity is stratified by IBS-SSS score as 
follows: normal: <75; mild: 75 to <175; moder-
ate: 175 to <300; severe: ⩾300.17 The IBS-QOL 
is a disease-specific measure with an overall score 
ranging from 0 to 100 and eight subscale scores, 
with lower scores indicating lower quality of life. 
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An increase in IBS-QOL score of 14 points is con-
sidered to represent a clinically meaningful 
improvement.18,19 The EQ-5D-3L is a standard-
ised measure of general health status with two 
components: the EQ-5D index score, reported on 
a scale of 0–1, with higher scores indicating better 
health state, and the EQ visual analogue scale 
(VAS), reported on a scale of 0–100, with higher 
scores indicating better health.20
Participants were requested to self-complete the 
validated IBS-SSS questionnaire17 at baseline 
(up to a maximum of 3 days following initiation 
of linaclotide treatment) and at 4 (±1), 12 (±4) 
and 52 (±4) weeks after treatment initiation 
with linaclotide, and to complete the validated 
IBS-QOL19 and the EQ-5D-3L21 at baseline and 
at 12 (±4) and 52 (±4) weeks after linaclotide 
initiation. At each time point when study ques-
tionnaires were completed, participants also 
completed a questionnaire on laxative use, 
whether they were still taking linaclotide treat-
ment and, if relevant, the date and reason for 
linaclotide discontinuation. A patient was 
recorded as having discontinued linaclotide 
treatment if they indicated that they were taking 
linaclotide for fewer than 4 days per week.
Safety assessments. All adverse events (AEs) and 
adverse drug reactions that occurred during the 
study period were documented by participating 
physicians or by enrolled patients via patient 
questionnaires. AEs reported by physicians were 
assessed for seriousness and severity and whether 
a causal relationship to linaclotide could not be 
excluded; patient-reported AEs were not assessed 
for severity.
Physician-reported AEs were defined as serious if 
they met any of the following criteria: results in 
death; is life-threatening; requires inpatient hos-
pitalisation or prolongs existing hospitalisation 
results in persistent or significant disability or 
incapacity; is a congenital anomaly or birth defect; 
is any other medically important event that may 
jeopardise the patient or may require intervention 
to prevent one of the other preceding outcomes; 
or any suspected transmission via a medicinal 
product of an infectious agent.
Statistical analyses
A sample size of approximately 150–200 
patients was considered adequate to detect a 
statistically significant reduction of ⩾50 points 
in the IBS-SSS score.17 The primary endpoint 
was assessed at 12 weeks, and so a sample size 
of 190–250 participants was planned to account 
for the possibility of up to 20% of participants 
discontinuing within the first 12 weeks and not 
completing the 12-week questionnaire, based 
on discontinuation rates observed in previous 
studies.22
Data were summarised using descriptive statistics 
and the significance of within-patient changes 
from baseline in IBS-SSS score and other quanti-
tative outcomes were assessed using paired t tests. 
A response to linaclotide was defined as a reduc-
tion in overall IBS-SSS score of ⩾50, or a reduc-
tion in score to less than 150 for patients with a 
baseline score of ⩾150.23 Data from patients 
without paired questionnaires at both baseline 
and a given time point (4 weeks, 12 weeks or 
52 weeks) were excluded from the analysis. Data 
were analysed using Microsoft Excel 2010© and 
Stata 14.2®.
Results
Baseline patient demographics and clinical 
characteristics
Overall, the study invited 230 patients with IBS-C 
to participate across eight centres. Of these invited 
patients, 202 consented to participate, with 151 
(74.7%) patients meeting the Rome III diagnostic 
criteria for IBS. Of the 202 patients, 41 (20.3%) 
reported continuing on linaclotide treatment at 
52 weeks (Figure 1). A further 87 (43.1%) 
patients reported discontinuing linaclotide treat-
ment before 52 weeks. The remaining 74 patients 
did not provide a complete 52-week question-
naire (n = 42), did not return a 52-week ques-
tionnaire for analysis (n = 29) or were lost to 
follow up (n = 3).
Among the 87 patients discontinuing before 
52 weeks, the primary reason was AEs in 51 
(25.2%) patients, followed by lack of efficacy in 
18 (8.9%) patients. Thirty-eight patients had dis-
continued by 4 weeks, with 33 discontinuing 
between 4 and 12 weeks, and 16 discontinuing 
after 12 weeks of treatment.
Of the 202 patients enrolled, 124 had paired IBS-
SSS data for the completed questionnaires at both 
baseline and 12 weeks, with 76 having baseline 
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and 52-week paired IBS-SSS data (Figure 1). Of 
the 76 patients with paired data at 52 weeks, 34 
continued on linaclotide treatment and 42 reported 
they had discontinued linaclotide treatment.
The median (range) age at baseline was 44.9 
(18.1–77.2) years, and the majority of partici-
pants (n = 185; 91.6%) were female (Table 1). 
The median time since diagnosis was 0.21 years. 
Figure 1. Participant flow.
IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale.
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Table 1. Baseline demographics and clinical characteristics.
Total
(N = 202)
Female, n (%) 185 (91.6)
Median age (range), years 44.9 (18.1–77.2)
Median time since diagnosis of IBS-C (range), years 0.21 (0–67.7)
Abdominal symptoms, n (%)a  
 Constipation 198 (98.0)
 Abdominal pain 169 (83.7)
 Bloating 167 (82.7)
 Diarrhoea 27 (13.4)
Comorbidities (occurring in ⩾4% of patients), n (%)a  
 Gastroenterology and hepatology 35 (17.3)
 Obstetrics and gynaecology 12 (5.9)
 Cardiovascular 9 (4.5)
Medications for IBS taken in the 12 months prior to 
linaclotide initiation (reported by ⩾5% of patients), n (%)a
 
 Laxatives 158 (78.2)
 Antispasmodics 34 (16.8)
 Tricyclic antidepressants 24 (11.9)
Medications for IBS continued at linaclotide initiation 
(reported by ⩾5% of patients), n (%)a
 
 Laxatives 84 (41.6)
 Antispasmodics 16 (7.9)
 Tricyclic antidepressants 12 (5.9)
Mean IBS-SSS score (SD)b 339 (92)
IBS severity based on IBS-SSS score at baseline, n (%)b  
 In remission (IBS-SSS score <75) 1 (0.5)
 Mild (IBS-SSS score 75 to <175) 9 (4.7)
 Moderate (IBS-SSS score 175 to <300) 54 (28.0)
 Severe (IBS-SSS score ⩾300) 129 (66.8)
aNot mutually exclusive.
bData available in 193 patients.
IBS, irritable bowel syndrome; IBS-C, irritable bowel syndrome with constipation; IBS-SSS, Irritable Bowel Syndrome 
Symptom Severity Scale; SD, standard deviation.
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Figure 2. Change in IBS-SSS score in the overall population and by baseline severity at 12 weeks (a) and 
52 weeks (b).
aScored from 0 to 500; bincludes six patients with IBS-C classified as mild at baseline; cincludes four patients with IBS-C 
classified as mild at baseline.
IBS-C, irritable bowel syndrome with constipation; IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale; SD, 
standard deviation.
The mean (standard deviation) IBS-SSS score at 
baseline was 339 (92), and the majority of patients 
(n = 129; 66.8%) had severe IBS-C, based on a 
baseline IBS-SSS score of ⩾300. The most com-
mon medication being taken for IBS at the time 
of linaclotide treatment initiation and continued 
during the treatment period was laxatives, 
reported by 84 (41.6%) patients. Antispasmodics 
and tricyclic antidepressants were continued at 
linaclotide initiation by 7.9% and 5.9% of 
patients, respectively.
Effect of linaclotide treatment on IBS-SSS score
Change from baseline in IBS-SSS score at week 
12 and week 52. Among the 124 patients with 
paired baseline and week 12 data, including 
those who had discontinued linaclotide prior to 
week 12 and those still continuing on treat-
ment, the mean IBS-SSS score was significantly 
reduced from baseline to 12 weeks after lina-
clotide initiation, with a mean [95% confidence 
interval (CI)] change of −77.0 (−96.3, −57.7; 
p < 0.001) [Figure 2(a)]. A similar reduction 
was seen among patients with paired data at 
week 52: mean IBS-SSS score was significantly 
reduced from baseline to 52 weeks, with a 
mean (95% CI) change of −70.7 (−95.0, −46.5; 
p < 0.001) [Figure 2(b)].
Of the patients with paired IBS-SSS data at week 
12, 91 had a reduced IBS-SSS score at week 12 
Y Yiannakou, A Agrawal et al.
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versus baseline, with 66 meeting the threshold of a 
reduction of ⩾50 points. Four patients had no 
change in score, and 29 had an increased score, 
indicating worsening symptoms. Of the 76 
patients with paired IBS-SSS data at week 52, 55 
experienced a decrease in IBS-SSS score versus 
baseline, with 40 experiencing a decrease of ⩾50 
points. One patient had no change in score and 
20 patients had an increase in score.
At week 12, a greater mean (95% CI) change from 
baseline in IBS-SSS score was observed in patients 
with severe IBS-C [−90.7 (−115.8, −65.7); 
p < 0.001] compared with patients with moderate 
IBS-C [−65.7 (−96.4, −35.0); p < 0.001] and the 
overall population [Figure 2(a)]. Similar results 
were seen at week 52, with a greater mean (95% 
CI) change in patients with severe IBS-C [−91.1 
(−125.8, −56.5); p < 0.001] versus patients with 
moderate IBS-C [−57.2 (−90.7, −23.8); p < 0.01] 
and the overall population [Figure 2(b)].
When patients with paired 52-week data were 
stratified according to whether they continued on 
linaclotide treatment or had discontinued before 
52 weeks, the mean (95% CI) change in IBS-SSS 
score from baseline to week 52 was significant 
both in patients continuing on linaclotide treat-
ment [−94.2 (−129.8, −58.5); p < 0.001] and in 
patients who had discontinued linaclotide [−51.8 
(−85.1, −18.5); p < 0.01] (Figure 3).
Response to linaclotide treatment. At 12 and 
52 weeks, 55.6% and 53.9% of patients, 
respectively, with paired data displayed a response 
to linaclotide treatment (Figure 4). The propor-
tion of responders at week 12 and week 52 was 
broadly similar to the overall population, both in 
patients reporting moderate IBS-C symptoms at 
baseline (57.9% and 46.7%, respectively) and in 
patients reporting severe symptoms at baseline 
(55.0% and 59.5%, respectively).
Effect of linaclotide treatment on quality of life
Changes in IBS-QOL score at 12 and 52 weeks.  
Linaclotide treatment significantly improved 
IBS-QOL total scores, with a mean (95% CI) 
change from baseline of 8.7 (5.8, 11.6) points 
(p < 0.001) at 12 weeks and 12.2 (8.3, 16.0) 
points (p < 0.001) at 52 weeks [Figure 5(a)]. 
A significant improvement of approximately 
10–15 points versus baseline was seen at both 
12 and 52 weeks after linaclotide treatment ini-
tiation across all subscales of the IBS-QOL 
(p < 0.05 for all comparisons) [Figure 5(b)]. 
The greatest mean (95% CI) changes at week 
52 were seen for the health worry and dyspho-
ria subscales, with improvements of 15.1 (10.0, 
20.3) and 12.8 (8.3, 17.3) points, respectively.
Changes in EQ-5D-3L at 12 and 52 weeks. Mean 
EQ-5D index overall scores were significantly 
increased from baseline to week 12, with a mean 
(95% CI) change of 0.09 (0.05, 0.13) points 
(p < 0.001), but were similar from baseline to 
week 52, with a mean (95% CI) change of 
−0.005 (−0.05, 0.06; p > 0.1) [Figure 6(a)]. 
Figure 3. Change in IBS-SSS score at 52 weeks in patients continuing or discontinuing linaclotide.
aScored from 0 to 500.
IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale.
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Figure 4. Response to linaclotide in the overall population and by baseline severity at 12 weeks (a) and 
52 weeks (b). Response to linaclotide was defined as a reduction in IBS-SSS overall score of ⩾50, or a 
reduction in score to <150 for patients with a baseline score of ⩾150.
aIncludes six patients with IBS-C classified as mild at baseline; bincludes four patients with IBS-C classified as mild at 
baseline.
IBS-C, irritable bowel syndrome with constipation; IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale.
EQ-VAS overall scores were also significantly 
improved following linaclotide treatment initia-
tion, with a mean (95% CI) change from base-
line of 7.9 (4.0, 11.8) points (p < 0.001) at week 
12 and 6.1 (0.03, 12.2) points (p < 0.05) at 
week 52 [Figure 6(b)].
Safety
Overall, 77 (38.1%) patients reported 174 AEs 
during the 52-week study (Table 2). The most 
commonly reported AEs were diarrhoea (26.7%), 
abdominal pain (10.4%) and abdominal distention 
(6.4%). By week 12, 47 (23%) patients had dis-
continued the study due to AEs, and by 52 weeks, 
this number had increased to 51 patients (26%).
Of the AEs reported, 73 (42.0%) were assessed 
as not serious, 8 (4.6%) were serious and the 
remainder (93; 53.4%) had no assessment of 
seriousness recorded. The eight serious AEs were 
as follows: two events of spontaneous abortion 
occurring in one patient (1.1%; relationship to 
study drug unknown); one event of diarrhoea 
occurring in each of two patients (1.1%; both con-
sidered drug related); and one event in one patient 
each of abdominal discomfort (considered drug 
related), abdominal pain (considered drug 
related), constipation (relationship to study drug 
unknown) and rectal bleeding (considered proba-
bly drug related) [0.6% each].
A post hoc analysis demonstrated that 42 (50%) 
patients with baseline laxative use reported at 
least one AE during the study period, compared 
with 35 (30%) among patients not reporting 
baseline laxative use. AEs of diarrhoea were also 
more common in patients with baseline laxative 
use (32%) versus patients without baseline laxa-
tive use (20%). However, a F2 test showed that 
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the association between baseline laxative use and 
experiencing AEs of diarrhoea within 12 weeks of 
treatment initiation was not significant (odds 
ratio: 1.86; p = 0.057).
Discussion
The efficacy and safety of linaclotide were 
assessed in patients with moderate to severe 
IBS-C in the real-world setting in this 1-year, 
prospective, observational, open-label study con-
ducted in gastroenterology and specialist surgical 
departments of secondary and tertiary care cen-
tres in the UK. Baseline patient characteristics, 
including severity scores and prior medication 
use, suggest that the patient cohort in this study 
experienced IBS-C symptoms towards the more 
severe end of the spectrum and may have been 
refractory to prior treatment. Symptom severity 
assessed with the IBS-SSS was significantly 
reduced compared with baseline at 12 and 
52 weeks of linaclotide treatment among patients 
with paired data. These reductions were observed 
in patients with moderate IBS-C and with severe 
IBS-C, with a slightly greater change from base-
line to week 12 and week 52 seen in patients with 
severe IBS-C versus the moderate subgroup and 
the overall population. Patients withdrawing 
from linaclotide therapy were offered other ther-
apy options, although these were not recorded as 
Figure 5. IBS-QOL overall score at 12 and 52 weeks (a) and change from baseline in IBS-QOL overall score 
and domain scores at 12 and 52 weeks (b).
aScored from 0 to 100 (higher scores indicate better functioning).
*p < 0.05; **p < 0.01; ***p < 0.001.
CI, confidence interval; IBS-QOL, Irritable Bowel Syndrome Quality of Life; SD, standard deviation.
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part of the study, which may have been responsi-
ble for the reduction in severity at 52 weeks 
in the overall population, observed irrespective 
of whether patients had reported that they dis-
continued linaclotide treatment prior to 52 weeks 
or continued on treatment.
Current guidance from the UK National Institute 
for Health and Care Excellence for the diagnosis 
and management of IBS states that linaclotide 
should be considered if optimal or maximal toler-
ated doses of previous laxatives from different 
classes have not helped and the patient has had 
constipation for at least 12 months.24 In line with 
these guidelines, nearly 80% of patients in this 
study had used laxatives within the 12 months 
prior to linaclotide initiation, with approximately 
40% still taking laxatives at the time of linaclo-
tide initiation. As treatment failure in patients 
with IBS-C is known to result in increased health 
care resource use and costs,12 the finding from 
this study that linaclotide treatment is able to sig-
nificantly reduce symptom severity is important.
The present data support the previously reported 
findings of two large phase III clinical trials of 
linaclotide in over 1500 patients with moderate to 
severe IBS-C, which demonstrated significant 
reductions in IBS severity with linaclotide treat-
ment versus placebo.15,16 These data are also in 
line with the results from an observational study 
of linaclotide conducted in clinical practice in 
Germany (N = 375), where linaclotide treatment 
led to significant reductions in intensity of abdom-
inal pain and bloating and improved bowel move-
ment frequency versus baseline.25
The threshold for improvement in IBS-SSS overall 
score in this study was a reduction of ⩾50 points, 
in line with numerous studies making use of the 
Figure 6. EQ-5D index overall score at 12 and 52 weeks (a) and EQ-VAS score at 12 and 52 weeks (b).
aScored from 0 to 1 (1 indicates full health); bscored from 0 to 100 (higher scores indicate better health state).
EQ-5D, EuroQol five dimension; EQ-VAS, EuroQol visual analogue scale; SD, standard deviation.
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IBS-SSS and the original description of this meas-
ure.17,26–30 However, a single study based on a 
cohort of 277 patients with IBS has suggested that 
a change of 95 points might represent a minimal 
clinically important difference.31 A 50% improve-
ment from baseline in IBS-SSS score has also been 
proposed as a responder definition; however, this 
criterion requires further validation.32–34
Linaclotide treatment also led to significant 
improvements in quality of life. Pooled analysis of 
the linaclotide phase III trials demonstrated that 
linaclotide led to significant improvements versus 
placebo in quality of life, as assessed with the IBS-
QOL,35 with over half of linaclotide-treated 
patients displaying a response after 12 weeks of 
treatment. These findings are supported by the 
significant improvements seen in IBS-QOL total 
score and across all subscales in the present study 
at both 12 and 52 weeks.
The most common AEs reported with linaclotide 
treatment in the present study were diarrhoea and 
abdominal pain. The safety profile observed with 
Table 2. Summary of AEs, regardless of relationship to study drug.
Total
(N = 202)
Total number of AEs 174
Patients with ⩾1 AE, n (%)a 77 (38.1)
 Not seriousb 73 (42.0)
 Seriousb 8 (4.6)
 No assessment of seriousness recordedb 93 (53.4)
AEs occurring in ⩾1.5% of patients, n (%)c  
 Diarrhoead 54 (26.7)
 Abdominal pain 21 (10.4)
 Abdominal distension 13 (6.4)
 Anal incontinence 8 (4.0)
 Nausea 8 (4.0)
 Defecation urgency 5 (2.5)
 Dyspepsia 5 (2.5)
 Headache 5 (2.5)
 Vomiting 4 (2.0)
 Condition aggravated 3 (1.5)
 Constipation 3 (1.5)
 Gastrointestinal sounds abnormal 3 (1.5)
 Malaise 3 (1.5)
 Muscle spasms 3 (1.5)
aIncludes AEs where the relationship to study drug is related, probable, possible or unknown. 
bExpressed as a proportion of 174 events reported.
cExpressed as number of events (percentage of patients).
dIncludes events of loose stools coded as diarrhoea.
AE, adverse event.
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linaclotide in this 1-year study is similar to that 
seen in the phase III trials, with no signs of addi-
tional adverse events developing as a result of pro-
longed use.15,16 AEs of diarrhoea that were related, 
probably or possibly related, or unrelated to the 
study drug were reported in 26.7% of patients in 
the present study, and were reported (regardless 
of relatedness) in 19.5% and 19.7% of patients in 
the two phase III studies, respectively.15,16 The 
higher incidence of diarrhoea observed in this 
study may be attributable to approximately 40% 
of patients continuing laxative use after linaclotide 
initiation. In the present study, AEs of diarrhoea 
were more common among patients with baseline 
laxative use versus patients without. These find-
ings are in line with the recommendation that lina-
clotide should not be coadministered with laxatives 
at the start of treatment.14
At 52 weeks, a high proportion of patients had 
discontinued treatment with linaclotide. The 
majority of patients discontinuing linaclotide 
treatment did so within the first 4 weeks, with 
only a small proportion of patients who contin-
ued on linaclotide after 12 weeks subsequently 
discontinuing. The most common reason for 
discontinuation was AEs, occurring in 25.2% of 
patients. In the two phase III studies, 7.9% and 
10.2% of patients in the linaclotide treatment 
group discontinued due to a treatment-emer-
gent AE.15,16 The higher rate of discontinua-
tions due to AEs reported in the present study 
may be attributable to the manner in which the 
data were collected. Patients indicated whether 
they had taken linaclotide for fewer than 4 days 
over the past week; if they answered ‘yes’, they 
were considered to have discontinued. However, 
this could have been a temporary interruption of 
treatment and not a permanent discontinuation. 
Furthermore, this was a low-intensity, observa-
tional study with limited face-to-face study 
visits, and higher discontinuation rates may 
therefore be expected compared to those seen in 
a phase III study with more intensive patient 
follow up and more frequent patient contact. 
These results may therefore represent a more 
‘real-world’ outcome.
The findings of this study should also be inter-
preted in the light of other limitations. First, the 
study was observational in nature and did not 
have a comparator group. The study also enrolled 
a number of patients who did not meet Rome III 
criteria and a small number of patients with IBS 
that was mild or in remission at baseline; such 
patients would typically be excluded from a phase 
III trial, but are reflective of the population with 
IBS seen in clinical practice. Second, the findings 
may have been influenced by confounding fac-
tors, such as changes in concomitant medica-
tions, including laxatives, or initiation of 
alternative medications after linaclotide discon-
tinuation, which were not recorded during the 
study. For instance, patients were not required to 
cease laxative use at baseline, and the types of 
laxatives used were not collected from the trial 
population. Furthermore, patients discontinuing 
linaclotide treatment and initiating an alternative 
treatment option may have continued to return 
study questionnaires after stopping linaclotide. 
Third, completed patient questionnaires were 
not available for every patient at every time point, 
meaning that analyses are based only on data 
from those patients who had paired question-
naires. Finally, the study sample size was calcu-
lated to ensure sufficient power for the primary 
analysis. However, due to patient discontinua-
tions and paired data not being available for every 
patient, other statistical analyses may not have 
been appropriately powered and should be con-
sidered descriptive only.
Overall, the results of this 1-year, prospective, 
observational, open-label study represent the first 
report of a 1-year, real-world study of linaclotide 
in the UK, and demonstrate that linaclotide treat-
ment is effective in improving the severity of 
IBS-C with a favourable and consistent safety 
profile. There was a high rate of discontinuations 
in this study, partly related to the prevalence of 
AEs of diarrhoea, with patients not showing a 
response typically discontinuing early, and those 
continuing on treatment maintaining a response. 
These data support the findings of the linaclotide 
phase III clinical trials and show that the findings 
translate into the real-world setting of secondary 
and tertiary care centres in the UK.
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